GenVec cancer drug trial suspended

GenVec yesterday announced it suspended a trial of its TNFerade cancer treatment after one of the trial participants died, even though a link between the drug and the death has not been proven. Eight trial participants with esophageal cancer were being treated with high doses of the drug in combination with radiation and three of them developed blood clots. One of the three died and the case was "potentially related" to the drug, according to a study summary. "We want to make sure there is not a pattern here we should be concerned about," GenVec's CEO said. "Our first and foremost concern is always patient safety."

View Full Article in:

Washington Post (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ